key: cord-0715632-g97351fy
authors: Yuan, Dan; Gao, Wenfeng; Liang, Shu; Yang, Shujuan; Jia, Peng
title: Biosafety threats of the rapidly established labs for SARS-CoV-2 tests in China
date: 2020-07-14
journal: Environ Int
DOI: 10.1016/j.envint.2020.105964
sha: eac69175958ed3547588ede26e184788fca25035
doc_id: 715632
cord_uid: g97351fy

To increase the capacity of identifying coronavirus disease 2019 (COVID-19) infection, many Biosafety Level 2 (BSL-2) labs have been established in a short period of time for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid tests all over the world. However, their biosafety has not been evaluated, which could have been the first gateway to SARS-CoV-2 transmission. During 9-11 March, 2020, the first comprehensive evaluation of the biosafety in all 89 labs qualified for conducting SARS-CoV-2 tests in Sichuan Province of China was conducted. The degree of compliance with 39 criteria in five categories was evaluated: biosafety requirements for lab activities (14 criteria), sample transfer, acceptance and management (6 criteria), waste management (9 criteria), personnel training and protection (4 criteria), and lab environmental disinfection, emergency plans and accident handling (6 criteria). Our results revealed that, although an overall median compliance rate of 94.6% for 39 criteria, only four of 89 labs met all of them. Criteria in personnel training and protection have been most satisfactorily met, followed by lab environmental disinfection, emergency plans and accident handling. The most severe risk was the lack of automatic doors at the main entrance or in core operation areas, especially among labs in CDC and hospitals. This risk, together with failure for keeping pressure in the core operation areas 25±5 Pa (mainly among labs in the third-party testing agencies), may cause accidental exposure to biological agents from lab activities. Other severe risk included failure for standard labeling of SARS-CoV-2 wastes and lacking regular monitoring of sterilization effects. Our findings would provide experiences and lessons for strengthening lab biosafety in other Chinese provinces, and also serve as an important reference for many other countries where such labs are being or will be quickly built for fighting the COVID-19.

February 2020, which could develop a severe acute respiratory syndrome with serious clinical 38 symptoms, including fever, dry cough, dyspnea, respiratory disorders, and pneumonia, and 39 may result in progressive respiratory failure and death. 3 The World Health Organization 40 (WHO) declared it as a pandemic on 11 th March 2020 when more than 118,000 cases, 41 including over 4000 deaths, were confirmed in 114 countries worldwide. 4 In addition to the 42 human movement resulting in person-to-person contact, 5,6 the geo-environmental factors have 43 also been identified as determinants of the accelerated diffusion and severity of 7 44 To prepare for a long fight against the COVID-19, we need to intensity every link in the 45 chain of COVID-19 control and prevention. Working largely unseen, pathogenic Commented [JP(1]: Further revisions to better the draft:

1. An improved abstract and list of keywords (highlighted) 2. Three citations in the main text (highlighted) 3. Revisions in Conclusions (tracked) microorganism labs will have been playing a vital role as the first gateway in nucleic acid testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from beginning to the end of this pandemic. To increase the capacity of identifying SARS-CoV-2 infections, 49 many Biosafety Level 2 (BSL-2) labs for testing SARS-CoV-2 have been established or 50 adapted from the existing pathogenic microorganism labs in a short period of time all over the 51 world. However, the potential biological hazards from such rapidly built labs could threaten 52 the safety of lab workers and consequently all citizens, e.g., leakage of infectious agents 53 outside the labs. The biological accidents in pathogenic microorganism labs have occasionally 54 occurred since 1897. 8 According to the US governmental data on biosafety in the labs, during 55 2008-2012, there had been plenty of accident (e.g., spills, record-keeping errors) occurring 56 between 100 to 275 potential releases of pathogens each year in labs that handle select agents, 57 although few lab workers were reported to be infected. 9 The largest accident of lab-acquired Although the risk of LAIs is usually lower and the quality and safety measures are higher in 63 diagnostic labs than in research labs, those accidents indicate that biosafety of pathogenic 64 microorganism labs remains a serious concern to the public and community health.

Although it remains unknown how many SARS-CoV-2 LAIs have occurred among the of biological agents and hence should be eradicated.

According to these results from our comprehensive evaluation, there were various 148 biosafety risks in many aspects of those newly established labs for SARS-CoV-2 tests, and 149 any problem could lead to unpredictable biosafety accidents. Early detection of these 150 problems can effectively reduce or even avoid these potential risks. In addition to overcoming 151 those problems, it is more important to have deeper reflection on how to strengthen the 152 current biosafety system, in order to avoid such biological hazards fundamentally and cost-153 effectively. We suggest to strengthen the biosafety system in the following aspects: Items colored in grey, yellow, orange, and red represent the compliance rates of 90-95%, 85-90%, 80-85%, and <80%, respectively.

*Not applicable to 19 BSL-2 labs, with 8 in CDCs, 9 in hospitals, and 2 in third-party testing agencies

We thank Sichuan Provincial Health Commission, Sichuan Public Health Law Supervision Enforcement, and Sichuan Center for Disease Control and Prevention for their organization of this timely evaluation across the province. We also thank the International Institute of Spatial Lifecourse Epidemiology (ISLE) for research support.